Distribution of Topical Nasal Medication Within the Nasal Cavity and Sinuses by Radiographic Comparison

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-03-12

Study Completion Date

2009-01-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the distribution of nasal sprays and nasal drops when used.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Sinusitis

NCT06076304

Sinus Infection Acute Sinusitis

RECRUITING PHASE4

Role of Imaging in Complications of Sinusitis

NCT05836935

Rhinosinusitis Intracranial Extension Rhinosinusitis Chronic +4 more

UNKNOWN NA

Point-of-Care Computed Tomography (CT) Chronic Rhinosinusitis Study

NCT00871286

Chronic Rhinosinusitis

COMPLETED NA

Effect of Topical Sinonasal Antibiotics

NCT03935828

Chronic Rhinosinusitis (Diagnosis) Antibiotic Side Effect

WITHDRAWN PHASE2

Amphotericin B Suspension in Refractory Chronic Sinusitis

NCT00425620

Chronic Sinusitis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to determine the distribution of nasal sprays and nasal drops when used. The study hypothesizes that nasal drops will reach the frontonasal region more often than nasal sprays.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Sinusitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nasal spray

This arm of the study will contain subjects who will spray 2-4 sprays of a nasal contrast solution in their nares. Following administration of the spray, the subjects will then have a Xoran mini-CAT scan of their sinuses.

Group Type EXPERIMENTAL

Sinus CT Scan

Intervention Type RADIATION

Subjects will undergo a Xoran miniCAT scan of their sinuses

Omnipaque 240 Contrast Solution

Intervention Type DRUG

Subjects will spray 2-4 drops of half-strength Omnipaque 240 mgI/mL into each nare. Each spray is approximately 0.1 ml.

Nasal drop

This arm will contain subjects who will place two drops of a nasal contrast solution in each nose. Following administration of the nasal contrast, the subjects will then have a Xoran miniCAT scan of their sinuses.

Group Type EXPERIMENTAL

Sinus CT Scan

Intervention Type RADIATION

Subjects will undergo a Xoran miniCAT scan of their sinuses

Omnipaque 240 mg I/mL

Intervention Type DRUG

Subjects will place two drops of half-strength Omnipaque 240 mg I/mL intranasally to each nose. Each drop is approximately 1 ml.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sinus CT Scan

Subjects will undergo a Xoran miniCAT scan of their sinuses

Intervention Type RADIATION

Omnipaque 240 Contrast Solution

Subjects will spray 2-4 drops of half-strength Omnipaque 240 mgI/mL into each nare. Each spray is approximately 0.1 ml.

Intervention Type DRUG

Omnipaque 240 mg I/mL

Subjects will place two drops of half-strength Omnipaque 240 mg I/mL intranasally to each nose. Each drop is approximately 1 ml.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

contrast enhancement contrast enhancement

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* adult able to perform activities of daily living

Exclusion Criteria

* signs or symptoms of acute or chronic paranasal sinus disease
* history of sinus surgery
* symptomatic deviated septum
* active seasonal allergies
* allergies to contrast
* history of nasal polyposis
* pregnant or breast feeding women
* neck or back problems that would prevent a subject from kneeling on the floor and crouching over
* currently taking metformin or amiodarone
* students or stff under the direct supervision of the investigators
* cognitive impairment
* terminal illness

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes